Cargando…
Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years
IMPORTANCE: SARS-CoV-2 vaccines are authorized for use in most age groups. The safety of SARS-CoV-2 vaccines is unknown in children younger than 5 years. OBJECTIVE: To retrospectively evaluate the safety of the BNT162b2 vaccine used off-label in children younger than 5 years compared with the safety...
Autores principales: | Toepfner, Nicole, von Meißner, Wolfgang C. G., Strumann, Christoph, Drinka, Denisa, Stuppe, David, Jorczyk, Maximilian, Moor, Jeanne, Püschel, Johannes, Liss, Melanie, von Poblotzki, Emilie, Berner, Reinhard, Moor, Matthias B., Chao, Cho-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579908/ https://www.ncbi.nlm.nih.gov/pubmed/36255723 http://dx.doi.org/10.1001/jamanetworkopen.2022.37140 |
Ejemplares similares
-
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in children under 5 years
por: Strumann, Christoph, et al.
Publicado: (2023) -
Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
por: Eduarda Andrade e Andrade, Maria, et al.
Publicado: (2022) -
BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021) -
Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers
por: Greco, Marilena, et al.
Publicado: (2021) -
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)